Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

http://www.wikidata.org/entity/Q39704965

about

SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer Metabolism of kidney cancer: from the lab to clinical practice State of the science: an update on renal cell carcinoma Integrated molecular analysis of clear-cell renal cell carcinoma.Choosing the right cell line for renal cell cancer research Molecular genetics of clear-cell renal cell carcinoma Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma Altered nutrient response of mTORC1 as a result of changes in REDD1 expression: effect of obesity vs. REDD1 deficiency.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.BAP1 loss defines a new class of renal cell carcinoma.Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes.RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.DEPTOR ubiquitination and destruction by SCF(β-TrCP).High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma Hypoxia-inducible factor 1a is a Tsc1-regulated survival factor in newborn neurons in tuberous sclerosis complex Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.Tivozanib in the treatment of renal cell carcinoma.Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia.Molecular responses to hypoxia-inducible factor 1α and beyond.Crossing paths in Human Renal Cell Carcinoma (hRCC).Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Constitutive Glycolytic Metabolism Supports CD8(+) T Cell Effector Memory Differentiation during Viral Infection.Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes Classifying cancer genome aberrations by their mutually exclusive effects on transcription.Sunitinib resistance in renal cell carcinoma.Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma

P2860

Q24339492-93403BB2-9299-43A2-9677-3A9F647FAA92 Q24600512-5AECB39F-5AE3-4B15-84CF-C7EF69199AAD Q24630685-912DB321-A681-4982-9FE0-98F057319305 Q27852382-D7BA26A0-1F24-48F2-A2E5-6EF19DA92CAE Q28073283-24389AEF-B434-4214-BC84-D894ED92D152 Q33729097-6D91F5D8-612D-496A-AD73-62EA87051576 Q33947929-7CCA88E9-D008-49FB-AA18-3524D1CA6B44 Q34006278-D6C6CC7D-2B97-4172-8312-0AFA90B5216F Q34074997-A23E89D9-CCFA-49E3-B123-8EE63C76C5F1 Q34077263-20EB20D7-FB78-4428-88CD-6D1EA3D5520E Q34280223-EABC7B79-CD76-46FD-8CAF-DD4AE1A35B08 Q34414411-E1F9CEF7-0F41-4D14-9816-12EBADFB0703 Q35184503-0AF9E726-B9AF-449A-8D2F-7068F4F6F376 Q36169696-0FE45AC2-E465-4D12-AF55-2D9E7E190BDE Q36200219-0C8DB4CE-5E92-4CBB-99EC-56F0DFD9AFE5 Q36231927-60EB42E5-FD93-4BE9-B50A-DA5BDB0ADC96 Q36606040-A3920262-4F73-4203-AB1D-EEA98FF1F19F Q36731382-B030E561-C25F-4F3D-91B3-A22C501718FE Q36815312-B3CB7B6B-D331-48F0-B4FF-0740F2911641 Q36933605-7FB8B167-A97D-40EE-9B37-D794C8780FEC Q37010342-274CD46F-C80A-4235-A6C2-8D7EB952A475 Q37217474-970C95FC-70FE-41BD-9E8F-218D41E3F82F Q37549140-E74A29E2-ED21-4BFC-99C4-D76E3CFC0678 Q37654508-9CE256D2-B137-490B-887E-20F4C96A64A4 Q37708123-C491AEF6-533C-4F36-A3C1-72E1D07E75D0 Q38064316-3E092144-1CEF-469B-84F8-781318F3C167 Q38794217-3B1119E7-8A92-4353-98A9-B0AA3557A326 Q39008859-A8B03C46-3D19-4E2C-A290-FEF039E49EF6 Q39194568-78EF3C52-99BE-4B98-9DD4-6BEC4A4E8BCF Q39798868-F806D8EB-F274-4DA1-916F-D23EF687C511 Q41911531-B409A9CF-A550-4E85-801D-954642598D8F Q41975337-3B39DBD6-FAA1-4E91-978D-79B6EF6FF29A Q42140758-0EAB6CE4-48AA-4E16-87B4-39D1A527CA19 Q49365385-F29E867B-2A32-415D-92B9-6F6C56A511D3 Q51763292-C58F301C-0D0C-4428-B4E4-E48567FE7F15 Q55419613-5977D359-710F-4C37-925F-FC9A95DDF36D Q59135881-B4FDEE2C-0462-4C55-AAA2-DC5550151724

P2860

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

http://www.wikidata.org/entity/Q39704965

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@en

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@nl

type

label

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@en

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@nl

prefLabel

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@en

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

@nl

P1433

Q39704965-95BDCD89-2115-4387-81A4-C136AFA6E087

P1476

Q39704965-B3E9BE5F-8C6B-402F-B21B-AF420484B885

P2093

Q39704965-0A217E65-5F03-4080-915E-BD9E18F98811

Q39704965-3522813E-4404-46A8-9590-9B9B41E53013

Q39704965-4589CB2C-3B3A-4B5D-A04F-A854277AF08F

Q39704965-83AF3327-96D1-4B82-81BC-788A4FB257DB

Q39704965-8C0E9641-4B6E-40F0-A369-547A9A7DFD51

Q39704965-96519356-C1DE-4702-A634-B2F99F613977

Q39704965-A9BE3D62-EB90-4488-B7B7-EE60E2BF1E66

Q39704965-C6E92107-74F4-480E-9C14-50148B0855C0

Q39704965-EB4B2485-BCF6-411F-90E9-AF32A6FD38A0

Q39704965-EE49964C-D337-4DCC-A8F2-7510349822F2

P2860

Q39704965-0618B1CE-AF14-40F7-A6E7-75AFAEDD4278

Q39704965-06817B65-EA6B-497B-B56E-F810288DF9A9

Q39704965-08C56AD8-6180-4CC8-9E3F-1ABF9D66C4F1

Q39704965-09E30A46-85F3-4709-8A19-98B388C5A157

Q39704965-0AB61323-D4CA-4050-9267-C6C0FE462DF4

Q39704965-143DB5B9-5957-4330-BCF9-C3331DDD8F74

Q39704965-15A0A8F7-7267-45F9-A8BF-463705A50636

Q39704965-17B09A95-E42A-4EF4-BA68-4CCC5B3C7353

Q39704965-183FD430-0D54-4A94-BDB1-3797CC47967C

Q39704965-208B7EA7-FDEB-40FA-9BCE-B48F396D87EA

P304

Q39704965-B782ADF9-B7ED-4899-9D93-F853D1CD3589

P31

Q39704965-04F3C7E1-EA05-4B8A-943B-386938A351E4

P356

Q39704965-BDAC578A-0900-412E-80DF-DC29B17DB601

P433

Q39704965-11FE61E4-1247-4E7C-B5F4-4F0752F2F95A

P478

Q39704965-0FDB24DA-DB1C-447C-BFAE-37C34DEDB3D7

P50

Q39704965-BEF6B13E-1ED7-407E-AFE8-AC2CECB3E4A9

Q39704965-F11D65DB-7579-4742-95B9-48ED02438713

P577

Q39704965-08ABC9BC-2F99-4538-8A20-6BF141B54234

P698

Q39704965-DEEF0206-B04D-4CA0-874D-D5710C18C260

P932

Q39704965-77200C62-4034-4B5E-948A-1E073C6E8652

P356

1541-7786.MCR-11-0302

P1433

Molecular Cancer Research

P1476

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma

@en

P2093

Blanka Kucejova

http://www.w3.org/2001/XMLSchema#string

James Brugarolas

http://www.w3.org/2001/XMLSchema#string

Nicholas C Wolff

http://www.w3.org/2001/XMLSchema#string

Payal Kapur

http://www.w3.org/2001/XMLSchema#string

Shane Alexander

http://www.w3.org/2001/XMLSchema#string

Toshinari Yamasaki

http://www.w3.org/2001/XMLSchema#string

Tram Anh T Tran

http://www.w3.org/2001/XMLSchema#string

Wareef Kabbani

http://www.w3.org/2001/XMLSchema#string

Xian-Jin Xie

http://www.w3.org/2001/XMLSchema#string

Yair Lotan

http://www.w3.org/2001/XMLSchema#string

P2860

Structural analysis and functional implications of the negative mTORC1 regulator REDD1

The RSK family of kinases: emerging roles in cellular signalling

Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Regulation of mTOR and cell growth in response to energy stress by REDD1.

Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

mTOR: from growth signal integration to cancer, diabetes and ageing

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

P304

1255-1265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-11-0302

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Samuel Peña-Llopis

Sharanya Sivanand

P577

2011-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21798997

http://www.w3.org/2001/XMLSchema#string

P932

3234675

http://www.w3.org/2001/XMLSchema#string